Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Oncopeptides AB ( (SE:ONCO) ).
Oncopeptides AB announced that a collaborative study on NK cell engagers, part of the Eurostars NKENGAGE project, will be presented at the American Society of Hematology Annual Meeting. The study explores a novel immunotherapeutic approach for multiple myeloma using NK cells, showing promising preclinical results with reduced toxicity compared to T-cell strategies. This recognition at ASH highlights Oncopeptides’ expansion beyond peptide-drug conjugates and its potential to address unmet needs in cancer treatment.
The most recent analyst rating on (SE:ONCO) stock is a Hold with a SEK5.50 price target. To see the full list of analyst forecasts on Oncopeptides AB stock, see the SE:ONCO Stock Forecast page.
More about Oncopeptides AB
Oncopeptides is a Swedish biotech company specializing in the research, development, and commercialization of targeted therapies for difficult-to-treat cancers. The company employs its proprietary Peptide Drug Conjugate (PDC) platform to create compounds that selectively deliver cytotoxic agents to cancer cells. Oncopeptides is also advancing new compounds through its PDC and SPiKE platforms, with its flagship drug being commercialized in Europe and partnerships in South Korea, the Middle East, and Africa.
Average Trading Volume: 3,926,090
Technical Sentiment Signal: Hold
Current Market Cap: SEK1.56B
For detailed information about ONCO stock, go to TipRanks’ Stock Analysis page.